Veerle De Herdt

Veerle De Herdt

Auto-generated profile, based on publicly available information

Veerle De Herdt

Department of Neurology, Ghent University Hospital , Ghent

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2007 in Epilepsia
Verified
Journal Article
Open access
PDF file
PBPaul Boon
Paul Boon
KVKristl Vonck
Kristl Vonck
VHVeerle De Herdt
Veerle De Herdt
ADAnnelies Van Dycke
Annelies Van Dycke
MGMaarten Goethals
Maarten Goethals
DRDirk Van Roost
Dirk Van Roost
Summary:  Purpose: This pilot study prospectively evaluated the efficacy of long‐term deep brain stimulation (DBS) in medial temporal lobe (MTL) structures in patients with MTL epilepsy. Methods: Twelve consecutive patients with refractory MTL epilepsy were included in this study. The protocol included invasive video‐EEG monitoring for ictal‐onset localization and evaluation for subsequent stimulation of the ictal‐onset zone. Side effects and changes in seizure frequency were carefully monitored. Results: Ten of 12 patients underwent long‐term MTL DBS. Two of 12 patients underwent selective amygdalohippocampectomy. After mean follow‐up of 31 months (range, 12–52 months), one of 10 stimulated patients are seizure free (>1 year), one of 10 patients had a >90% reduction in seizure frequency; five of 10 patients had a seizure‐frequency reduction of ≥50%; two of 10 patients had a seizure‐frequency reduction of 30–49%; and one of 10 patients was a nonresponder. None of the patients reported side effects. In one patient, MRI showed asymptomatic intracranial hemorrhages along the trajectory of the DBS electrodes. None of the patients showed changes in clinical neurological testing. Patients who underwent selective amygdalohippocampectomy are seizure‐free (>1 year), AEDs are unchanged, and no side effects have occurred. Conclusions: This open pilot study demonstrates the potential efficacy of long‐term DBS in MTL structures that should now be further confirmed by multicenter randomized controlled trials.

21 March 2011 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
RRRobrecht Raedt
Robrecht Raedt
RCRalph Clinckers
Ralph Clinckers
LMLies Mollet
Lies Mollet
KVKristl Vonck
Kristl Vonck
RTRiëm El Tahry
Riëm El Tahry
AMAlfred Meurs
Alfred Meurs

1 November 2017 in Trends in Food Science & Technology
Verified
Journal Article
Closed access
SLS. Lagast
S. Lagast
XGX. Gellynck
X. Gellynck
JSJoachim Schouteten
Joachim Schouteten
VHV. De Herdt
V. De Herdt
Hans De SteurHans De Steur
Hans De Steur

1 April 2009 in Neurotherapeutics
Verified
Journal Article
Closed access
PBPaul Boon
Paul Boon
RRRobrecht Raedt
Robrecht Raedt
VHVeerle de Herdt
Veerle de Herdt
TWTine Wyckhuys
Tine Wyckhuys
KVKristl Vonck
Kristl Vonck

1 September 2007 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
VHVeerle De Herdt
Veerle De Herdt
PBPaul Boon
Paul Boon
BCBerten Ceulemans
Berten Ceulemans
HHHenri Hauman
Henri Hauman
LLLieven Lagae
Lieven Lagae
KVKristl Vonck
Kristl Vonck

1 July 2004 in Journal Of Clinical Neurophysiology
Verified
Journal Article
Closed access
KVKristl Vonck
Kristl Vonck
VTVijay Thadani
Vijay Thadani
KGKaren Gilbert
Karen Gilbert
SDStefanie Dedeurwaerdere
Stefanie Dedeurwaerdere
LGLiesbeth De Groote
Liesbeth De Groote
PBPaul Boon
Paul Boon
Vagus nerve stimulation (VNS) is an alternative treatment for medically or surgically refractory epilepsy. The long-term efficacy and safety of VNS were evaluated in a large patient series at Ghent University Hospital and Dartmouth-Hitchcock Medical Center. Between March 1995 and February 2003, seizure frequency and type as well as prescribed antiepileptic drugs and side effects were prospectively assessed in 131 patients treated with VNS in either center. Patients with a minimum follow-up duration of 6 months were included in the efficacy and safety analysis. A total of 118 of 131 implanted patients had a minimum postimplantation follow-up period of 6 months (mean, 33 months). The mean age of these patients was 32 years and the mean duration of refractory epilepsy was 22 years. The mean reduction in monthly seizure frequency in all patients was 55% (range, 0–100; SD = 31.6). Seven percent of patients were free of seizures with impaired consciousness, 50% of patients had a seizure frequency reduction of more than 50%, and 21% of patients were nonresponders. Fifteen patients reported stimulation-related side effects such as hoarseness or gagging. In a large patient series from two geographically distinct epilepsy centers located in two different continents, VNS proved to be efficacious and safe during long-term follow-up.